Estrogen Metabolites on the DUTCH Test: 2-OH, 4-OH and 16-OH
The estrogen section of a DUTCH report is the part women most often bring to a consultation with a question — usually "is my estrogen going down the bad pathway?" — and the part most often over-sold by the practitioners who order it. The pathways are real. The chemistry behind "protective" and "harmful" is real. The evidence that the ratios predict anything for an individual woman, or should change her treatment, is thinner than the report's color-coding suggests. This page is the honest reading.
The main page covers the test as a whole; the on hormone therapy page covers what it can read in a woman already on estrogen. Genetics — the COMT variant that affects one of these steps — belongs to the methylation panel.
The three pathways
Estradiol and estrone are cleared by the liver in two stages. The first stage hydroxylates them — adds a hydroxyl group — at one of three positions on the molecule, producing three families of metabolite, and the position determines the family's chemistry.
2-hydroxy (2-OH). The largest pathway in most women. The 2-OH metabolites are weakly estrogenic and are readily neutralized in the second stage by methylation, which converts them to 2-methoxy estrogens — compounds with little estrogenic activity and, in laboratory work, some anti-proliferative properties. This is the pathway the reports call "protective."
4-hydroxy (4-OH). A smaller pathway. The 4-OH metabolites are more estrogenic and, if not methylated promptly, can be oxidized to reactive quinones that bind DNA. That chemistry — demonstrated in the laboratory and in animal models — is the basis of the concern about 4-OH and breast tissue. Methylation, again, is the neutralizing step, and the COMT page covers the enzyme responsible.
16-hydroxy (16-OH). The third pathway produces estriol and related metabolites, which are more strongly estrogenic than the 2-OH products and are associated with proliferative effects on tissue in laboratory studies. Historically this pathway was the "bad" one in the ratio literature.
The DUTCH test measures the metabolites of all three in urine and reports them as amounts and as ratios — most prominently 2-OH to 16-OH, and the proportion of 2-OH that has been methylated.
What the ratios are claimed to mean
The claim, in its strong form: a higher 2-OH:16-OH ratio is protective against breast cancer, a lower one is a risk, and a high 4-OH fraction is a risk that can be reduced by supporting methylation. Reports are color-coded on this basis and a large supplement market — cruciferous extracts, DIM, methyl donors — sells on the promise of shifting the ratio.
The chemistry makes the claim plausible. The next section is about whether the clinical evidence bears it out.
What the evidence supports
Less than the reports imply. The 2-OH:16-OH ratio was proposed as a breast cancer risk marker in the 1990s on the strength of small case-control studies, and larger prospective studies since have been inconsistent: some found a modest association between a higher 2-OH pathway and lower risk, particularly in premenopausal women; others found none; and a pooled analysis found the evidence insufficient to recommend the ratio for risk assessment. The 4-OH pathway has stronger laboratory support and weaker human data. No trial has shown that changing a woman's ratio — by diet, supplement or anything else — changes her breast cancer risk.
The ratios are also measured in urine on one day, and they vary with the menstrual cycle, with body weight, with alcohol, with smoking and with the microbiome. A single result is a snapshot of a moving target.
The honest summary: the pathways are biochemically real, the "protective" and "harmful" labels have a laboratory basis, the population data are inconsistent, and there is no evidence that acting on an individual woman's ratio improves any outcome. That is not nothing, and it is not what the color-coding says.
How it informs — and does not decide — HRT
We do not use estrogen metabolites to decide whether a woman is a candidate for hormone therapy, what she takes, or how it is given. Those decisions are made on her symptoms, her history, her baseline labs and the guideline evidence on the women's HRT page, and no guideline body includes metabolite ratios in them.
Where the metabolite panel informs: in a woman with a family history of breast cancer who wants every available piece of information before deciding, where a heavily 4-OH-weighted profile with poor methylation is one more input to a conversation that is already careful; in explaining why a woman with a strong 16-OH pathway has heavier estrogenic effects than her blood level predicts; and in the small number of cases where a profile prompts a closer look at the liver, the microbiome or the methylation cycle. It is context. A woman whose ratio is "unfavourable" is not thereby told she cannot have HRT, and a woman whose ratio is "favorable" is not thereby told she is safe — the breast cancer risk page covers what actually determines that.
And on the supplements: DIM and cruciferous extracts do shift the 2-OH pathway upward in small studies. Whether that shift does anything for a woman's health has not been shown, and "supporting methylation" with methyl donors is covered — and qualified — on the methylation page. We do not sell a ratio-fixing protocol.
Frequently asked questions
The breakdown products of estradiol and estrone through three liver pathways — 2-OH, 4-OH and 16-OH — measured in urine and reported as amounts and ratios.
The proportion of estrogen cleared through the 2-hydroxy pathway versus the 16-hydroxy pathway. Proposed as a breast cancer risk marker in the 1990s; larger studies since have been inconsistent and it is not used in risk assessment guidelines.
In the laboratory, 4-OH metabolites can form DNA-reactive compounds if not methylated. The human evidence that a high 4-OH fraction predicts cancer in an individual is weak. It is a reason for context, not alarm.
DIM and cruciferous extracts shift the 2-OH pathway upward in small studies. No trial shows the shift changes any health outcome.
No. Candidacy and choice of therapy are decided on symptoms, history, blood labs and guideline evidence. The metabolite profile is context in a careful conversation, not a gate.
Optional. It adds context for a woman who wants every input, particularly with a family history; it is not required and does not change the guideline-based decision.
Where this fits in your plan
The DUTCH Test page covers the test; the estrogen metabolites are its most over-read section. HRT decisions live on the women's HRT page, and the breast cancer risk page covers what actually determines that risk.
We measure first. Then we act.
References
- Eliassen AH et al. Urinary estrogens and estrogen metabolites and subsequent risk of breast cancer among premenopausal women. Cancer Research 2012;72:696–706.
- Samavat H, Kurzer MS. Estrogen metabolism and breast cancer. Cancer Letters 2015;356:231–243.
- Cavalieri E, Rogan E. The molecular etiology and prevention of estrogen-initiated cancers. Molecular Aspects of Medicine 2014;36:1–55.
- Ziegler RG et al. Epidemiologic studies of estrogen metabolism and breast cancer. Steroids 2015;99:67–75.
- Newman M, Curran DA. Reliability of a dried urine test for comprehensive assessment of urine hormones and metabolites. BMC Chemistry 2021;15:18.
- The Menopause Society. The 2022 Hormone Therapy Position Statement. Menopause 2022;29:767–794.
- Back toDUTCH® Test
- DUTCH test on hormone therapyUrine metabolites read some hormone routes well and others badly. Which HRT products the DUTCH test can and cannot interpret, when blood is the right test instead, and why topical progesterone is the trap.Read
- COMT and estrogenThe COMT gene neutralizes estrogen's reactive metabolites, and a common variant slows it. What that means, what is evidence and what is functional-medicine extrapolation, and why it does not decide hormone therapy.Read
- Estrogen and breast cancer riskThe boxed warning is gone; the question is not. What the WHI actually found for estrogen alone versus combined therapy, in absolute numbers, and what it means for you.Read
How we write and review our content
ACT 2 Health provides clinician-led care. Treatments are available only to eligible patients following clinical evaluation and within applicable regulations. This content is educational and is not medical advice. Individual results vary.
Diagnostic testing does not diagnose or rule out disease on its own and is interpreted by a licensed provider alongside your history and examination.
Care is delivered via telemedicine by healthcare professionals licensed in the state where the patient is located. Services are available only in states where our providers are licensed.